Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 5, 2011, Pages

  Shai, Shaw Yung ^a   Sukhanov, Sergiy ^a   Higashi, Yusuke ^a   Vaughn, Charlotte ^a   Rosen, Clifford J ^b   Delafontaine, Patrice ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JOSEPH HOSPITAL   (United States)

Author keywords

Apolipoprotein E; Chemokine receptors; Chemokines; Congenic mice; Growth factors; Vascular biology

Indexed keywords

ABC TRANSPORTER A1; ANGIOTENSIN CONVERTING ENZYME 2; APOLIPOPROTEIN E; BETA2 INTEGRIN; CD44V ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL; COLONY STIMULATING FACTOR 1; CUTANEOUS T CELL ATTRACTING CHEMOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR B; PROTEIN BAX; SCAVENGER RECEPTOR A; SOMATOMEDIN C; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET; DISEASE COURSE; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION PROFILING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; DISEASE MODELS, ANIMAL; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; RATS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955780684     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01081.2010     Document Type: Article

References (26)

1. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 160: 25-31, 2009.
2. Boquist S, Ruotolo G, Skoglund-Andersson C, Tang R, Bjorkegren J, Bond MG, de Faire U, Brismar K, Hamsten A. Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin Endocrinol (Oxf) 68: 51-58, 2008.
3. Bouxsein ML, Rosen CJ, Turner CH, Ackert CL, Shultz KL, Donahue LR, Churchill G, Adamo ML, Powell DR, Turner RT, Muller R, Beamer WG. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res 17: 570-579, 2002.
4. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24: 435-444, 2004.
5. DiStasi MR, Ley K. Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol 30: 547-556, 2009.
6. Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR. Aging is associated with greater nuclear NFκB, reduced IκBα, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 7: 805-812, 2008.
7. Friedrich N, Haring R, Nauck M, Ludemann J, Rosskopf D, Spilcke-Liss E, Felix SB, Dorr M, Brabant G, Volzke H, Wallaschofski H. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 94: 1732-1739, 2009.
8. Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metab Clin North Am 16: 995-1011, 1987.
9. Higashi Y, Peng T, Du J, Sukhanov S, Li Y, Itabe H, Parthasarathy S, Delafontaine P. A redox-sensitive pathway mediates oxidized LDLinduced downregulation of insulin-like growth factor-1 receptor. J Lipid Res 46: 1266-1277, 2005.
10. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P. IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 21: 245-254, 2010.
11. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106: 939-944, 2002.
12. Kadl A, Galkina E, Leitinger N. Induction of CCR2-dependent macrophage accumulation by oxidized phospholipids in the air-pouch model of inflammation. Arthritis Rheum 60: 1362-1371, 2009.
13. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS-/-Apoe-/- mice are ameliorated by enalapril treatment. J Clin Invest 105: 451-458, 2000.
14. Li Y, Higashi Y, Itabe H, Song YH, Du J, Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol 23: 2178-2184, 2003.
15. McNeill E, Channon KM, Greaves DR. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci (Lond) 118: 641-655, 2010.
16. Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol 33: 1777-1789, 2001.
17. Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musaro A. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J 21: 1393-1402, 2007.
18. Rosner B. Fundamentals of Biostatistics. Pacific Grove, CA: Duxbury, 2000, p. 511-532.
19. -/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol 30: 1916-1924, 2010.
20. LM. Mouse Genetics: Concepts and Applications. New York: Oxford Univ. Press, 1995, p. xiii.
21. Sonntag WE, Lynch CD, Cefalu WT, Ingram RL, Bennett SA, Thornton PL, Khan AS. Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. J Gerontol A Biol Sci Med Sci 54: B521-B538, 1999.
22. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27: 2684-2690, 2007.
23. Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A, Itadani H, Kotani H. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 278: 46654-46660, 2003.
24. -/- mice but does not reduce atherosclerosis. Endocrinology 150: 5478-5487, 2009.
25. Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide 10: 25-35, 2004.
26. Wickman A, Jonsdottir IH, Bergstrom G, Hedin L. GH and IGF-I regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. Eur J Endocrinol 147: 523-533, 2002.